LOS ANGELES – April 28, 2021 – Stand Up To Cancer® (SU2C) with its Scientific Partner, the American Association for Cancer Research, today announced internationally recognized expert in cancer immunotherapy research, James Gulley, MD, PhD, of the National Cancer Institute (NCI), part of the National Institutes of Health, as the newest member of the SU2C Scientific Advisory Committee.
Stand Up To Cancer’s Scientific Advisory Committee is composed of prestigious academic, government, industry, and advocacy leaders in cancer research. Its role is to provide insight and guidance to SU2C, setting the direction for its research initiatives, reviewing proposals for new grant awards, and conducting rigorous oversight of all active grants in the SU2C portfolio.
“Dr. Gulley has been an insightful reviewer for many of Stand Up To Cancer’s scientific teams,” said Nobel laureate Phillip A. Sharp, PhD, chair of Stand Up To Cancer’s Scientific Advisory Committee and an institute professor at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology. “His commitment to Stand Up To Cancer’s research efforts and expertise in immunotherapy will be a great addition to the Scientific Advisory Committee as we work to accelerate the pace of groundbreaking cancer research.”
In addition to his expertise in immunotherapy, Dr. Gulley has a strong interest in prostate cancer. As the chief of the Genitourinary Malignancies Branch and head of the Immunotherapy Section within the Center for Cancer Research at the NCI, he has made a significant impact in the clinical development of multiple immunotherapies and has led a number of first-in-human immunotherapy studies through phase 3 clinical trials.
Dr. Gulley also serves as the director of the Medical Oncology Service and deputy director of the Center for Cancer Research at the NCI. He serves on many boards and committees, including with the National Institutes of Health and with Loma Linda University Health, his alma mater. He has been an investigator on around 200 clinical trials, authored 350 scientific papers or chapters that have been cited around 20,000 times. His areas of expertise include therapeutic cancer vaccines, immune checkpoint inhibitors, clinical trials, combining immunotherapy with other therapies and immunotherapy for prostate cancer.
“We are thrilled that Dr. Gulley will be joining SU2C’s esteemed group of scientific experts,” said Sung Poblete, PhD, RN, CEO of Stand Up To Cancer. “His expertise and dedication to innovation in facilitating patient treatment will certainly inform SU2C’s immunotherapy research. SU2C was an early supporter of combination approaches to immunotherapy; Dr. Gulley’s expertise will drive our efforts as many of our current and future teams explore new immunotherapy advances and applications.”
# # #
Media Contact:
Mirabai Vogt-James
Stand Up To Cancer
mjames@su2c.org
Rick Buck
American Association for Cancer Research
rick.buck@aacr.org
About Stand Up To Cancer
Stand Up To Cancer® (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation, a 501(c)(3) charitable organization, was established in 2008 by media and entertainment leaders who utilize these communities’ resources to engage the public in supporting a new, collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. As of January 2021, more than 1,950 scientists representing more than 210 institutions are involved in SU2C-funded research projects.
Under the direction of our Scientific Advisory Committee, led by Nobel laureate Phillip A. Sharp, Ph.D., SU2C implements rigorous competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and ensure collaboration across research programs.
Current members of the SU2C Founders and Advisors Committee (FAC) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Sung Poblete, Ph.D., R.N., serves as SU2C’s CEO.
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes 48,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 127 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops—the largest of which is the AACR Annual Meeting, with more than 74,000 attendees for the 2020 virtual meetings and more than 22,500 attendees for past in-person meetings. In addition, the AACR publishes nine prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.
